Effects of estrogen on neuropathophysiology and behavior in Huntington's disease

描述（由申请人提供）：亨廷顿氏病（HD）是一种主要影响纹状体和皮质纹状体通路的遗传性、无法治愈的神经退行性疾病。小鼠和人类HD患者的性别差异表明，性腺类固醇激素可能在HD的发生和发展中发挥作用。17- 3-雌二醇（E2）的神经保护作用表明，它可能有助于这些性别差异。本研究的目的是表征E2对HD雌性小鼠神经病理生理和行为表型的影响。由于HD导致皮质纹状体通路的损伤和神经活动改变，皮层功能障碍可能导致纹状体中神经元活动过度和抗氧化维生素抗坏血酸（维生素C； AA）的缺乏。E2对谷氨酸（GLU）传递的影响可能使雌性HD小鼠皮质神经元活动正常化，防止纹状体AA丢失，导致雌性HD发病晚和/或进展慢。电生理和伏安法将被用来记录在前额叶皮层（PFC）的神经活动和监测AA释放纹状体的行为HD小鼠和野生型对照（WT）接受卵巢切除术(OVX) +。OVX + E2，或假手术+安慰剂。在皮质记录过程中，小鼠将参与一个反向学习任务，因为这是一个皮质纹状体依赖的任务，涉及ppf。E2神经保护的一种机制可能是通过上调胶质GLU转运体，如GLT1。这可能会防止被认为发生在HD中的GLU兴奋性毒性，并增加雌性HD小鼠的GLU清除率。免疫组织化学和行为评估将用于确定E2是否上调皮质和纹状体中的GLT1，改善雌性HD小鼠的行为表型。本研究结果将表明E2是否可以保护雌性HD小鼠纹状体AA缺失，使皮质神经元活动正常化，并改善与HD相关的行为表型。此外，结果将提示E2对GLU传播的影响是否导致HD小鼠中观察到的性别差异。在美国，有3万人患有HD，另有15万人有遗传该基因的风险。如果E2在HD模型中具有神经保护作用，那么它可能是一种合适的治疗方法，特别是对于患有HD的女性。此外，评估E2在调节大脑运动回路中的作用将更好地理解这种激素如何调节正常和病理运动控制。这一点尤其重要，因为超过4000万美国公民受到运动障碍的影响。E2可能在运动功能和神经保护中起着至关重要的作用，并可能代表一种目前尚未得到充分研究的运动障碍和神经退行性疾病的治疗方法。

DESCRIPTION (provided by applicant): Huntington's disease (HD) is a dominantly inherited, incurable neurodegenerative disease affecting primarily the striatum and corticostriatal pathway. Sex differences in mice and humans with HD suggest that gonadal steroid hormones may play a role in the onset and progression of HD. Neuroprotective effects of 17--3-estradiol (E2) suggest that it may contribute to these sex differences. The goal of the proposed research is to characterize the effects of E2 on neural pathophysiology and the behavioral phenotype of HD in female mice. Because HD results in damage and altered neural activity of the corticostriatal pathway, it is likely that cortical dysfunction contributes to excessive neuronal activity and a deficit of the antioxidant vitamin, ascorbate (vitamin C; AA) in the striatum. E2 effects on glutamate (GLU) transmission may normalize cortical neuronal activity in female HD mice preventing striatal AA loss and resulting in later onset and/or slower progression of HD in females. Electrophysiology and voltammetry will be used to record neural activity in the prefrontal cortex (PFC) and monitor AA release in the striatum of behaving HD mice and wild-type controls (WT) receiving either ovariectomy (OVX) + .placebo, OVX + E2, or sham surgery + placebo. During cortical recordings, mice will be engaged in a reversal learning task as this is a cortico- striatal dependent task involving PFC. One mechanism of E2 neuroprotection may be via upregulation of glial GLU transporters such as GLT1. This may prevent the GLU excitotoxicity believed to occur in HD and increase GLU clearance in female HD mice. Immunohistochemistry and behavioral assessments will be used to determine whether E2 upregulates GLT1 in the cortex and striatum, improving the behavioral phenotype of HD in female mice. Results of this study will indicate whether E2 may protect female HD mice from striatal AA loss, normalize cortical neuronal activity and improve the behavioral phenotype associated with HD. Furthermore, results will suggest whether E2 effects on GLU transmission contribute to sex differences observed in HD mice. HD affects -30,000 people in the United States and -150,000 more are at risk for inheriting the gene. If E2 is neuroprotective in HD models, it may be a suitable therapy, particularly for women with HD. Furthermore, evaluation of the role of E2 in regulating motor circuits in the brain will provide a better understanding of how this hormone regulates normal and pathological motor control. This is particularly important because more than 40 million U.S. citizens are affected by movement disorders. E2 likely plays a critical role in motor function and neuroprotection and may represent a therapy for movement disorders and neurodegenerative conditions that is currently not well investigated.